Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.

A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke (1993) 29.81

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia (1988) 14.61

Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA (2009) 4.42

Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31

Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol (2014) 3.96

Long-term mortality after stroke among adults aged 18 to 50 years. JAMA (2013) 3.84

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol (2010) 2.20

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet (2015) 2.09

Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.87

Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med (2007) 1.76

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol (2008) 1.69

Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem (2000) 1.52

Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol (2004) 1.48

Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res (1996) 1.42

Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet (2009) 1.30

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation (2013) 1.27

Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke (2007) 1.22

Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke (1994) 1.17

Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14

Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem (1996) 1.10

Recurrent ischemic events in young adults after first-ever ischemic stroke. Ann Neurol (2010) 1.07

Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke (1995) 0.93

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol (2015) 0.92

Management of Lp(a). J Clin Lipidol (2010) 0.86

Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets (2006) 0.84

Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep (2013) 0.81

Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica (2013) 0.81

Apolipoprotein(a) size polymorphism in young adults with ischemic stroke. Atherosclerosis (1999) 0.80

Genetic determination of lipoprotein(a) and its association with cardiovascular disease: convenient does not always mean better. J Intern Med (2014) 0.80

Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis (2015) 0.80

Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res (1992) 0.79

Lipoprotein (a) and risk of ischemic stroke in young adults. J Neurol Sci (2006) 0.78

Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. Int J Stroke (2013) 0.78

Lipoprotein (a) and the risk of ischemic stroke in young women. Atherosclerosis (2000) 0.78

Prime time for dissecting the entity of cryptogenic stroke. Stroke (2014) 0.77

Evaluation of the patient with unexplained stroke. Coron Artery Dis (2008) 0.77

International stroke genetics consortium recommendations for studies of genetics of stroke outcome and recovery. Int J Stroke (2021) 0.75